Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 3/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429012 | 1.00 | MEN1 (0.57) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL6431289 | 0.88 | MEN1 (0.61) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL6368127 | 0.87 | OPRM1 (0.57) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL31037193 | 0.87 | OPRM1 (0.57) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL6367791 | 0.86 | OPRM1 (0.56) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL6432366 | 0.85 | OPRM1 (0.57) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL6431416 | 0.84 | OPRM1 (0.54) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL6431423 | 0.84 | OPRM1 (0.54) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL6428974 | 0.82 | OPRM1 (0.54) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL6429015 | 0.82 | OPRM1 (0.52) | MEN1KMT2AOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250313604-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4611792-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3694536-B1 | A CELL-BASED SEEDING ASSAY FOR HUNTINGTIN AGGREGATION | UNIV CALIFORNIA (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | SPITFIRE PHARMA LLC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4593867-A2 | LONG-ACTING PARATHYROID HORMONE | Extend Biosciences, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4587045-A2 | THERAPEUTIC REGIMENS AND METHODS FOR REDUCING BODY WEIGHT IN A SUBJECT WITH FATTY LIVER DISEASE USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | ALTIMMUNE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4106796-A1 | GLP-1R AND GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | Spitfire Pharma LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-115427065-A | GLP-1R and GCGR agonists, formulations, and methods of use | 斯皮特弗尔制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | HERCULES CAPITAL, INC., AS AGENT | 2022-11-03 | — | — | US | disclosed |
| WO-2022178366-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | SPITFIRE PHARMA LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-4047023-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022125598-A1 | THERAPEUTIC REGIMENS AND METHODS FOR LOWERING BLOOD GLUCOSE AND OR BODY WEIGHT USING GLP-1R AND GCGR BALANCED AGONISTS | SPITFIRE PHARMA LLC (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220088124-A1 | COMPOSITIONS AND METHODS FOR TREATING NECROTIZING ENTEROCOLITIS | EMPIRE BIOTECHNOLOGIES, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| EP-2849567-B1 | CARRIERS FOR IMPROVED DRUG DELIVERY | EXTEND BIOSCIENCES INC (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | MEN1 1359/4885KMT2A 576/4885OPRM1 609/4885 |
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | MEN1 1287/4885KMT2A 3889/4885OPRM1 3200/4885 |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | MEN1 1818/4885KMT2A 704/4885OPRM1 2270/4885 |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | MEN1 2329/4885KMT2A 2881/4885OPRM1 878/4885 |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | GLP1R, IAPP, GPR119 | MEN1 1281/4885KMT2A 4387/4885OPRM1 3875/4885 |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | GLP1R, GCGR, GPR119 | MEN1 2065/4885KMT2A 2583/4885OPRM1 579/4885 |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | MEN1 1876/4885KMT2A 4134/4885OPRM1 3252/4885 |
| US-20250313604-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | MEN1 1876/4885KMT2A 4134/4885OPRM1 3252/4885 |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | GLP1R, IAPP, GPR119 | MEN1 1281/4885KMT2A 4387/4885OPRM1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.